JO3609B1 - علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين - Google Patents

علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين

Info

Publication number
JO3609B1
JO3609B1 JOP/2015/0201A JOP20150201A JO3609B1 JO 3609 B1 JO3609 B1 JO 3609B1 JO P20150201 A JOP20150201 A JO P20150201A JO 3609 B1 JO3609 B1 JO 3609B1
Authority
JO
Jordan
Prior art keywords
treatment
androgen deprivation
deprivation therapy
associated symptoms
therapy associated
Prior art date
Application number
JOP/2015/0201A
Other languages
English (en)
Inventor
Thomas Benson Charles
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3609B1 publication Critical patent/JO3609B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

يوفر الاختراع الحالي طريقة لعلاج أعراض مرتبطة بالعلاج بالحرمان من الأندروجين تشتمل على إعطاء مريض في حاجة إلى هذا العلاج كمية فعالة من مركب له الصيغة I: الصيغة I، أو ملح منه مقبول صيدليًا
JOP/2015/0201A 2014-09-11 2015-08-25 علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين JO3609B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462049192P 2014-09-11 2014-09-11

Publications (1)

Publication Number Publication Date
JO3609B1 true JO3609B1 (ar) 2020-08-27

Family

ID=54151401

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2018/0072A JOP20180072A1 (ar) 2014-09-11 2014-09-11 علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
JOP/2015/0201A JO3609B1 (ar) 2014-09-11 2015-08-25 علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JOP/2018/0072A JOP20180072A1 (ar) 2014-09-11 2014-09-11 علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين

Country Status (23)

Country Link
US (4) US10758515B2 (ar)
EP (2) EP3191094B1 (ar)
JP (4) JP6893171B2 (ar)
KR (5) KR20210083370A (ar)
CN (4) CN106794178A (ar)
AP (1) AP2017009795A0 (ar)
AU (2) AU2015315431C1 (ar)
BR (2) BR112017002449B1 (ar)
CA (2) CA3067289C (ar)
EA (2) EA034553B1 (ar)
ES (1) ES2779978T3 (ar)
HK (1) HK1252811A1 (ar)
IL (3) IL279209B2 (ar)
JO (2) JOP20180072A1 (ar)
MA (1) MA45416A (ar)
MX (3) MX391447B (ar)
MY (2) MY198753A (ar)
NZ (1) NZ728612A (ar)
SG (2) SG11201701630VA (ar)
TW (1) TWI616201B (ar)
UA (1) UA120099C2 (ar)
WO (1) WO2016040234A1 (ar)
ZA (1) ZA201802680B (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
EP4096660A1 (en) * 2020-01-27 2022-12-07 EirGen Pharma Ltd. Tetrahydrocyclopenta[b]indole compounds for the treatment of renal disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004204800B8 (en) * 2003-01-13 2011-05-26 University Of Tennessee Research Foundation Large-scale synthesis of selective androgen receptor modulators
US20110237664A1 (en) 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9889110B2 (en) * 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
WO2007138048A1 (en) 2006-05-31 2007-12-06 Glaxo Group Limited Novel heterocyclic compounds
WO2008011072A2 (en) * 2006-07-19 2008-01-24 Osurf (Ohio State University Research Foundation) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
US7443672B2 (en) 2006-10-03 2008-10-28 Fu Zhun Precision Industry (Shen Zhen) Co., Ltd. Video graphics array (VGA) card assembly
UA98777C2 (en) * 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
TW200918521A (en) 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
US8420624B2 (en) 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
EP2489656A1 (en) * 2007-12-21 2012-08-22 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
EP2297100B1 (en) * 2008-05-16 2012-10-31 Eli Lilly & Company Tetrahydrocyclopenta[b]indole androgen receptor modulators
WO2009155481A1 (en) * 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AR078862A1 (es) * 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
CN102234287B (zh) * 2010-04-26 2015-08-05 上海阳帆医药科技有限公司 硝基咪唑类化合物、其制备方法和用途
JP2012149054A (ja) * 2010-12-27 2012-08-09 Dainippon Sumitomo Pharma Co Ltd Ｎ−置換−環状アミノ誘導体からなる医薬
PL2915804T3 (pl) * 2012-10-31 2019-09-30 Fujifilm Toyama Chemical Co., Ltd. Nowe pochodne aminy lub ich sole jako inhibitory tnf alfa
RU2695664C1 (ru) * 2013-12-09 2019-07-25 Юсб Байофарма Спрл Производные имидазопиридина в качестве модуляторов активности tnf
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين

Also Published As

Publication number Publication date
IL258651B (en) 2021-02-28
HK1252811A1 (en) 2019-06-06
AU2015315431B2 (en) 2018-03-08
ES2779978T3 (es) 2020-08-21
JP6938550B2 (ja) 2021-09-22
CA2956514A1 (en) 2016-03-17
AU2015315431A1 (en) 2017-03-09
KR102024493B1 (ko) 2019-09-23
EA201891008A2 (ru) 2018-09-28
ZA201802680B (en) 2020-08-26
US20190111039A1 (en) 2019-04-18
UA120099C2 (uk) 2019-10-10
EA034553B1 (ru) 2020-02-19
MX391447B (es) 2025-03-21
CA2956514C (en) 2023-04-18
JP2022000432A (ja) 2022-01-04
CA3067289A1 (en) 2016-03-17
JP2019089795A (ja) 2019-06-13
JP6893171B2 (ja) 2021-06-23
JP2023145479A (ja) 2023-10-11
MX373322B (es) 2020-05-21
IL250291B (en) 2020-09-30
US20170172992A1 (en) 2017-06-22
US10758515B2 (en) 2020-09-01
IL258651A (en) 2018-06-28
EP3191094B1 (en) 2020-02-19
KR20210083370A (ko) 2021-07-06
US10799478B2 (en) 2020-10-13
EP3375444A1 (en) 2018-09-19
EA201790220A1 (ru) 2017-07-31
JP2017527584A (ja) 2017-09-21
NZ728612A (en) 2018-03-23
US20240148694A1 (en) 2024-05-09
KR20170040338A (ko) 2017-04-12
TW201618782A (zh) 2016-06-01
BR122018007412B1 (pt) 2022-08-23
KR20180041268A (ko) 2018-04-23
IL279209B2 (en) 2023-02-01
CN113651797A (zh) 2021-11-16
EA033606B1 (ru) 2019-11-08
KR20190015628A (ko) 2019-02-13
MA45416A (fr) 2019-04-24
IL279209B (en) 2022-10-01
MY195767A (en) 2023-02-10
MX2021014120A (es) 2022-01-04
TWI616201B (zh) 2018-03-01
IL250291A0 (en) 2017-03-30
CA3067289C (en) 2023-04-04
AU2018202714A1 (en) 2018-05-17
JOP20180072A1 (ar) 2019-01-30
CN106794178A (zh) 2017-05-31
US20200390744A1 (en) 2020-12-17
WO2016040234A1 (en) 2016-03-17
AU2015315431C1 (en) 2018-08-02
BR112017002449A2 (pt) 2017-12-05
SG10201809673RA (en) 2018-12-28
MX2017003140A (es) 2017-05-23
EA201891008A3 (ru) 2019-03-29
AU2018202714B2 (en) 2019-06-20
BR112017002449B1 (pt) 2022-08-09
IL279209A (en) 2021-01-31
JP7349480B2 (ja) 2023-09-22
KR20220132669A (ko) 2022-09-30
CN113521068A (zh) 2021-10-22
EP3191094A1 (en) 2017-07-19
KR102619415B1 (ko) 2024-01-02
CN108440497A (zh) 2018-08-24
AP2017009795A0 (en) 2017-03-31
MY198753A (en) 2023-09-23
SG11201701630VA (en) 2017-03-30

Similar Documents

Publication Publication Date Title
PH12017500493A1 (en) Combination therapy
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
MX365950B (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MY192055A (en) Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
PH12014502065A1 (en) Vesicular formulations
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX374354B (es) Método de curación de heridas.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2019004200A (es) Terapia de combinacion.
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
IN2014DE00818A (ar)
HK1233917A1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
PH12014000105A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds
IN2014DE00822A (ar)